Baricitinib + Tocilizumab
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Juvenile Idiopathic Arthritis
Conditions
Systemic Juvenile Idiopathic Arthritis
Trial Timeline
Feb 12, 2020 → Sep 1, 2026
NCT ID
NCT04088396About Baricitinib + Tocilizumab
Baricitinib + Tocilizumab is a phase 3 stage product being developed by Eli Lilly for Systemic Juvenile Idiopathic Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04088396. Target conditions include Systemic Juvenile Idiopathic Arthritis.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Juvenile Idiopathic Arthritis were approved
Approved (10) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04088396 | Phase 3 | Recruiting |
Competing Products
20 competing products in Systemic Juvenile Idiopathic Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 32 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 35 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 40 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 29 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 21 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 26 |
| Micafungin | Astellas Pharma | Phase 2 | 35 |
| E6742 | Eisai | Phase 1/2 | 32 |
| KHK4827 | Kyowa Kirin | Phase 1 | 29 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 40 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 40 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 47 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 32 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 40 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 27 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 32 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 29 |